Literature DB >> 25609773

Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support.

Sjoukje I Lok1, Fay M A Nous2, Joyce van Kuik2, Petra van der Weide2, Bjorn Winkens3, Hans Kemperman4, Andre Huisman2, Jaap R Lahpor5, Roel A de Weger2, Nicolaas de Jonge6.   

Abstract

OBJECTIVES: During support with a left ventricular assist device (LVAD), partial reverse remodelling takes place in which fibrosis plays an important role. In this study, we analysed the histological changes and expression of fibrotic markers in patients with advanced heart failure (HF) during continuous-flow LVAD (cf-LVAD) support.
METHODS: In 25 patients, myocardial tissue at the time of LVAD implantation (pre-LVAD) was compared with tissue from the explanted left ventricle (post-LVAD). Interstitial fibrosis and cardiomyocyte size were analysed pre- and post-LVAD. Plasma was obtained from all patients before and during LVAD support. Plasma levels, cardiac mRNA and protein expression of brain natriuretic peptide (BNP), galectin-3 (Gal-3), connective tissue growth factor (CTGF), osteopontin (OPN) and transforming growth factor β-1 were determined.
RESULTS: Fibrosis increased during cf-LVAD unloading (P < 0.05). Cardiomyocytes elongated (P < 0.05), whereas cross-sectional area did not change. BNP, Gal-3, CTGF and OPN were significantly elevated pre-LVAD in comparison with controls. BNP decreased significantly after 1 month of cf-LVAD support (P < 0.001) to near-normal levels. Pro-fibrotic markers remained elevated in comparison with controls.
CONCLUSIONS: cf-LVAD support is associated with lengthening of cardiomyocytes, without alterations in diameter size. Remarkably, myocardial fibrosis increased as well as circulating pro-fibrotic markers. Whether the morphological changes are a direct effect of reduced pulsatility during cf-LVAD support or due to HF progression requires further investigation.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Biomarkers; Fibrosis; Heart failure; LVAD; Reverse remodelling

Mesh:

Substances:

Year:  2015        PMID: 25609773     DOI: 10.1093/ejcts/ezu539

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  12 in total

Review 1.  Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.

Authors:  Shweta R Motiwala; Hanna K Gaggin
Journal:  Curr Heart Fail Rep       Date:  2016-10

Review 2.  The Inflammatory Response to Ventricular Assist Devices.

Authors:  Gemma Radley; Ina Laura Pieper; Sabrina Ali; Farah Bhatti; Catherine A Thornton
Journal:  Front Immunol       Date:  2018-11-15       Impact factor: 7.561

3.  Myofibrillolysis and fibrosis predicts myocardial insufficiency.

Authors:  Jerzy Pacholewicz; Michał Zakliczyński; Jerzy Nożyński; Paweł Nadziakiewicz; Michał Zembala; Marian Zembala
Journal:  Kardiochir Torakochirurgia Pol       Date:  2019-06-28

4.  Changes of myocardial gene expression and protein composition in patients with dilated cardiomyopathy after immunoadsorption with subsequent immunoglobulin substitution.

Authors:  Sabine Ameling; Gourav Bhardwaj; Elke Hammer; Daniel Beug; Leif Steil; Yvonne Reinke; Kerstin Weitmann; Markus Grube; Christiane Trimpert; Karin Klingel; Reinhard Kandolf; Wolfgang Hoffmann; Matthias Nauck; Marcus Dörr; Klaus Empen; Stephan B Felix; Uwe Völker
Journal:  Basic Res Cardiol       Date:  2016-07-13       Impact factor: 17.165

Review 5.  Galectin-3 and sST2 as Prognosticators for Heart Failure Requiring Extracorporeal Life Support: Jack n' Jill.

Authors:  Jianli Bi; Vidu Garg; Andrew R Yates
Journal:  Biomolecules       Date:  2021-01-27

6.  Degenerative changes of the aortic valve during left ventricular assist device support.

Authors:  Mareike Barth; Linus Mrozek; Naima Niazy; Jessica Isabel Selig; Udo Boeken; Yukiharu Sugimura; Nikolaos Kalampokas; Patrick Horn; Ralf Westenfeld; Patric Kröpil; Hug Aubin; Artur Lichtenberg; Payam Akhyari
Journal:  ESC Heart Fail       Date:  2021-12-21

Review 7.  Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence.

Authors:  Carlotta Sciaccaluga; Nicolò Ghionzoli; Giulia Elena Mandoli; Flavio D'Ascenzi; Marta Focardi; Serafina Valente; Matteo Cameli
Journal:  Biomolecules       Date:  2022-02-19

8.  Multi-Strain Probiotics Inhibit Cardiac Myopathies and Autophagy to Prevent Heart Injury in High-Fat Diet-Fed Rats.

Authors:  Chao-Hung Lai; Cheng-Chih Tsai; Wei-Wen Kuo; Tsung-Jung Ho; Cecilia-Hsuan Day; Pei-ying Pai; Li-Chin Chung; Chun-Chih Huang; Hsueh-Fang Wang; Po-Hsiang Liao; Chih-Yang Huang
Journal:  Int J Med Sci       Date:  2016-03-30       Impact factor: 3.738

9.  Moderate exercise training attenuates aging-induced cardiac inflammation, hypertrophy and fibrosis injuries of rat hearts.

Authors:  Po-Hsiang Liao; Dennis Jine-Yuan Hsieh; Chia-Hua Kuo; Cecilia-Hsuan Day; Chia-Yao Shen; Chao-Hung Lai; Ray-Jade Chen; V Vijaya Padma; Wei-Wen Kuo; Chih-Yang Huang
Journal:  Oncotarget       Date:  2015-11-03

10.  Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy.

Authors:  Paweł Rubiś; Sylwia Wiśniowska-Śmialek; Ewa Wypasek; Barbara Biernacka-Fijalkowska; Lucyna Rudnicka-Sosin; Ewa Dziewiecka; Patrycja Faltyn; Lusine Khachatryan; Aleksandra Karabinowska; Artur Kozanecki; Lidia Tomkiewicz-Pająk; Piotr Podolec
Journal:  Inflamm Res       Date:  2016-08-11       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.